.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,440,194

« Back to Dashboard

Details for Patent: 8,440,194

Title:Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid.RTM. or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Feb 19, 2008
Application Number:12/070,451
Claims:1. A method of treating leukemia in a human, which comprises administering to a human having leukemia escalating doses of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, wherein a starting dose is between about 2.5 mg/day and about 10 mg/day, and a maximum dose is between about 5 mg/day and about 50 mg/day, wherein the leukemia is chronic lymphocytic leukemia.

2. The method of claim 1, wherein the leukemia is relapsed, refractory or resistant to conventional therapy.

3. A method of treating leukemia in a human, which comprises administering to a human having leukemia escalating doses of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, wherein a starting dose is between about 2.5 mg/day and about 10 mg/day, and a maximum dose is between about 5 mg/day and about 50 mg/day, and a therapeutically effective amount of a second active agent, wherein the leukemia is chronic lymphocytic leukemia.

4. The method of claim 3, wherein the second active agent is an antibody, hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, or corticosteroid.

5. The method of claim 3, wherein the second active agent is rituximab, fludarabine, or a combination thereof.

6. The method of claim 5, wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered after the administrations of rituximab and fludarabine.

7. The method of claim 1 or 3, wherein the maximum amount of 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is from about 5 to about 10 mg per day.

8. The method of claim 7, wherein the maximum amount of 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is about 10 mg per day.

9. The method of claim 1 or 3, wherein the maximum amount of 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is about 5, 6, 7, 8, 9, 10, 15, 20, or 50 mg per day.

10. The method of claim 1 or 3, wherein 3-(4-amino -oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is enantiomerically pure.

11. The method of claim 10, wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is S enantiomer.

12. The method of claim 10, wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is R enantiomer.

13. The method of claim 1 or 3, wherein 3-(4-amino -oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in the form of a capsule or tablet.

14. The method of claim 1 or 3, wherein 3-(4-amino -oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in an amount of about 2.5to 10 mg per day for 21 days followed by seven days rest in a 28 day cycle.

15. The method of claim 14, further comprising administration of rituximab in an amount of 375 mg/m.sup.2.

16. The method of claim 1 or 3, wherein 3-(4-amino -oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered orally.

17. The method of claim 1 or 3, wherein 3-(4-amino -oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in the form of a capsule.

18. The method of claim 17, wherein the 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in the capsule of 5 mg, 10 mg, 15 mg, or 25 mg.

19. The method of claim 17, wherein the capsule comprises the 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

20. The method of claim 1 or 3, wherein the starting dose of 3-(4-amino-1-oxo-1,3-dihydro-iusoindol-2-yl)-piperidine-2,6-dione is escalated each week.

21. The method of claim 1 or 3 wherein the starting dose of 3-(4-amino-1-oxo-1,3-dihydro-iusoindol-2-yl)-piperidine-2,6-dione is escalated every 28 days.

22. The method of claim 3 wherein the second active agent is dexamethasone, prednisone, or a combination thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc